Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Cancer Research

- PMLiVE

AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader

The candidate has shown promising preclinical anti-tumour activity in drug- and TKI-resistant tumours

- PMLiVE

Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m

Paediatric low-grade gliomas are the most common type of brain tumour diagnosed in children

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

Bayer symbol

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

- PMLiVE

Phesi publishes new analysis revealing top five most studied diseases globally

The analysis also showed that 32% of phase 2 trials were terminated in the first half of 2024

- PMLiVE

Ipsen gains global rights to Foreseen’s ADC candidate in deal worth up to $1.03bn

FS001 is currently completing the final stages of preclinical development

- PMLiVE

WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer

In more than nine out of ten cases, the HPV virus leads to cervical cancer, the fourth most common cancer in women globally

- PMLiVE

Hologic survey reveals major screening action gap in millions of US women

An estimated 72 million women in the US have skipped or delayed recommended preventative screening

- PMLiVE

Study reveals GLP-1s could reduce risk of cancer in patients with type 2 diabetes

GLP-1 treatment reduced the risk of gallbladder cancer by 65% and meningioma by 63%

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links